Pharmacy World and Science

, Volume 26, Issue 5, pp 282–288 | Cite as

Development of a community pharmacy-based model to identify and treat OTC drug abuse/misuse: a pilot study

  • Glenda F. Fleming
  • James C. McElnay
  • Carmel M. Hughes


Objective: The aim of this study was to develop and pilot a harm-minimisation model for the identification and treatment of over-the-counter (OTC) drug abuse/misuse by community pharmacists.

Method: Extensive consultation was conducted during thedevelopment of the model. This included an exploratory conference involving an interdisciplinary group of delegates and detailed individual consultation with a range of healthcare practitioners. Consultation with a psychologist specialising in communication skillsallowed development of the communication aspects of the model. A comprehensive manual detailing the model was prepared.

Results: The model is designed to be used by communitypharmacists in conjunction with other healthcare professionals. It focuses on the abuse/misuse of opioids, laxatives and antihistamines and can be broadly divided into three phases, namely: patient identification and recruitment, treatment/referrals and datacollection/outcome measurement. Client identification is via record-keeping which is implemented alongside an information campaign promoting safe use of OTC medicines. Once identified, the pharmacist aims to recruit clients using the developed communication strategies. Treatment depends on whether the problem is misuse or abuse and on the product. Several treatment paths are available including treatment according to an agreed protocol and referring to the GP or community addiction team (CAT). Two pharmacists were recruited and trained to pilot the model. Of the clients, 18 were identified as abusing/misusingOTC products over a one-month period. The subject of inappropriate OTC use was raised with 14 of these clients. Some success was noted in that clients agreed to stop using the product and/or to try safer alternatives. As expected, some sales had to be refused, as the client was unwilling to accept the pharmacist’s intervention.

Conclusion: This study represents the first reportedstructured attempt by community pharmacists in the UK to address the abuse/misuse of OTC medication. Work is now ongoing to modify this model in light of the pilot study findings.

Abuse Community pharmacy Harm minimisation Medicine misuse Non-prescription products Northern Ireland Over-the-counter products 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ball K, Wilde M. OTC medicines misuse in West Cumbria. Pharm J 1989; 242: 40.Google Scholar
  2. 2.
    Paxton R, Chapple P. Misuse of over-the-counter medicines: a survey in one English County. Pharm J 1996; 256: 313–5.Google Scholar
  3. 3.
    Hughes GF, McElnay JC, Hughes CM. Abuse / misuse of non-prescription drugs. Pharm World Sci 1999; 21: 251–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Kennedy M. Cardiac glycoside toxicity: an unusual manifesta-tion of drug addiction.Med J Aust 1981; 2: 686–9.PubMedGoogle Scholar
  5. 5.
    Seow SSW. Abuse of APF linctus codeine and cardiac glycoside toxicity. Med J Aust 1984; 140: 54.Google Scholar
  6. 6.
    Thurston D, Taylor K. Gee's linctus. Pharm J 1984; 233: 63.Google Scholar
  7. 7.
    Mason AB, Pugh SE, Holt DW. Cardiac glycoside toxicity result-ing from cough linctus abuse. Hum Toxicol 1987; 6: 251–2.PubMedGoogle Scholar
  8. 8.
    Barragry JM, Morris DV. Fatal dependence on kaolin and mor-phine mixture. Postgrad Med J 1980; 56: 180–1.PubMedGoogle Scholar
  9. 9.
    Eknoyan G. Current status of chronic analgesic and nonsterio-dal anti-inflammatory drug nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 182–8.PubMedGoogle Scholar
  10. 10.
    Noels LM, Elseviers MM, De Broe ME. Impact of legislative meas-ures on the sales of analgesics and the subsequent prevalence of analgesic nephropathy: a comparative study in France, Sweden and Belgium. Nephrol Dial Transplant 1995; 10: 167–74.PubMedGoogle Scholar
  11. 11.
    De Broe ME, Elseviers MM, Bengtsson U, Mihatsch MJ, Molzahn M, Pommer Wet al. Analgesic nephropathy. Nephrol Dial Transplant 1996; 11: 2407–8.PubMedGoogle Scholar
  12. 12.
    Elseviers MM, De Broe ME. Analgesic nephropathy: is it cause by multi-analgesic abuse or single substance use? Drug Saf 1999; 20: 15–24.PubMedGoogle Scholar
  13. 13.
    Gott PH. Cyclizine toxicity-intentional drug abuse of a propri-etary antihistamine. N Engl J Med 1968; 279: 596.Google Scholar
  14. 14.
    Bassett KE, Schunk JE, Insley Crouch B. Cyclizine abuse by teen-agers in Utah. Am J Emerg Med 1996; 14 (5): 472–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Rowe C, Verjee Z, Koren G. Adolescence dimenhydrinate abuse: resurgence of an old problem. J Adolesc Health 1997; 21: 47–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Backer RC, McFeeley P, Wohlenberg N. Fatality resulting from cyclizine overdose. J Anal Toxicol 1989; 13: 308–9.PubMedGoogle Scholar
  17. 17.
    Clarke RF, Vance MV. Massive diphenhydramine poisoning re-sulting in a wide-complex tachycardia: successful treatment with sodium bicarbonate. Ann Emerg Med 1992; 21: 318–21.PubMedGoogle Scholar
  18. 18.
    Winn RE, McDonnell KP. Fatality secondary to massive overdose of dimenhydrinate. Ann Emerg Med 1993; 22: 1481–4.PubMedGoogle Scholar
  19. 19.
    Gardner DM, Kutcher S. Dimenhydrinate abuse among adoles-cents. Can J Psychiatry, 1993; 38: 113–6.PubMedGoogle Scholar
  20. 20.
    Brown JE, Sigmundson HK. Delirium from misuses of dimenhy-drinate. Can Med Assoc J 1969; 101: 49–50.Google Scholar
  21. 21.
    Atkinson MK. Misuse of cyclizine. Pharm J 1985; 235: 773.Google Scholar
  22. 22.
    Moriarty KJ, Silk DBA. Laxative abuse. Digest Dis 1988; 6: 15–29.Google Scholar
  23. 23.
    Vanin JR, Saylor KE. Laxative abuse: a hazardous habit for weight control. College Health 1989; 37: 227–30.Google Scholar
  24. 24.
    Meyers AM, Feldman C, Sonnekus MI, Ninin DT, Margolius LP, Whalley NA. Chronic laxative abusers with pseudo-idiopathic oedema and autonomous pseudo-bartter's syndrome: a spec-trum of metabolic madness, or new lights on an old disease? S Afr Med J 1990; 78: 631–6.PubMedGoogle Scholar
  25. 25.
    Muller-Lissner SA. Adverse effects of laxatives: fact and fiction. Pharmacology 1993; 47 (1 Suppl): 138–45.PubMedGoogle Scholar
  26. 26.
    Baker EH, Sandle GI. Complications of laxative abuse. Annu Rev Med 1996; 47: 127–34.CrossRefPubMedGoogle Scholar
  27. 27.
    DerMarderosian A, Brudnicki SM. The misuse and abuse of OTC laxatives. Am Druggist 1996; 213 (1): 49–55.Google Scholar
  28. 28.
    Wright LF, DuVal JW. Renal injury associated with laxative abuse. South Med J 1987; 80: 1304–6.PubMedGoogle Scholar
  29. 29.
    Copeland P M. Renal failure associated with laxative abuse. Psychother Psychosom 1994; 62: 200–2.PubMedGoogle Scholar
  30. 30.
    Krupski J, Pincus KT. Laxative induces nephropathy: a case re-port. J Pharmacoepidemiology 1996; 5 (1): 39–44.Google Scholar
  31. 31.
    Pharmaceutical Society of Northern Ireland. Ethics and Practice: A Guide for Pharmacists in Northern Ireland. 1997 edition. Bel-fast: Pharmaceutical Society of Northern Ireland 1997: 34–6.Google Scholar
  32. 32.
    Temple D J. Harm-reduction. Chemist Druggist 1996; 245: 730–1.Google Scholar
  33. 33.
    De Almeida Neto AC, Benrimoj SI, Gomel M, Fois R. Inappropri-ate self-medication practices: a pharmacy based intervention. J Soc Admin Pharm 1996; 13: 131–8.Google Scholar
  34. 34.
    Miller WR, Rollnick S. Motivational interviewing: preparing peo-ple to change addictive behaviour. London: The Guildford Press 1991.Google Scholar
  35. 35.
    Prochaska JO, DiClemente CC. The transtheoretical approach: crossing traditional boundaries of therapy. Illinois: Dow Jones-Irwin, 1984.Google Scholar
  36. 36.
    Ware Jr J, Snow K, Kosinski M, Gandek B. SF36 health survey. Manual and interpretation guide. Boston: Nimrod Press, 1993.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Glenda F. Fleming
    • 1
  • James C. McElnay
    • 2
  • Carmel M. Hughes
    • 2
  1. 1.Research and Development Office, 12-22BelfastNorthern Ireland
  2. 2.School of PharmacyThe Queen\'s University of BelfastBelfastNorthern Ireland E-mail

Personalised recommendations